01/26
Headlines

NASDAQ:PTIE

Today’s Hot List : Baidu (NASDAQ:BIDU), BlackBerry Ltd (NASDAQ:BBRY), Pain Therapeutics (NASDAQ:PTIE), Inland Real Estate Corp. (NYSE:IRC), City Holding Co. (NASDAQ:CHCO)

Mark Doerr03 mins

Baidu Inc (ADR) (NASDAQ:BIDU), Chinese web services company, has launched a new service that will help retailers to advertise on mobile devices for all the users of Baidu search engine, Reuters reported. This new feature will increase Baidu Inc (ADR) (NASDAQ:BIDU)’s revenues and will give it a huge boost in the market, as according to the statistics issued by the Chinese…

Read More

Best Stocks : Pain Therapeutics (NASDAQ:PTIE), Symantec (NASDAQ:SYMC), Hormel Foods (NYSE:HRL), Overstock.com Inc. (NASDAQ:OSTK), The Travelers. (NYSE:TRV)

Jayne Crisman02 mins

Pain Therapeutics Inc. (NASDAQ:PTIE), announced recently that they expect to start a Phase 1 clinical trial with ORADUR®-Hydromorphone shortly with an expectation of starting a Phase 3 trial for this product candidate in 2015.  Other programs, some of which are partnered and some of which are currently unpartnered, are progressing as well.” Pain Therapeutics Inc….

Read More

Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Richard Atkins02 mins

Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation…

Read More

Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Jayne Crisman03 mins

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an…

Read More